# Prestige Consumer Healthcare Inc. (PBH) Stock Analysis: 44% Upside Potential and Strong Buy Ratings

- Link: https://www.directorstalkinterviews.com/prestige-consumer-healthcare-inc-pbh-stock-analysis-44-upside-potential-and-strong-buy-ratings/4121262456
- Published: 2026-09-14T10:23:18+01:00
- Author: Madison Wilson

Prestige Consumer Healthcare Inc. (NYSE: PBH), a key player in the healthcare sector,
operates within the niche of drug manufacturers specializing in both specialty and
generic over-the-counter (OTC) products. With a market capitalization of $2.22 billion,
this New York-based company offers a wide array of products through its North American
and International OTC Healthcare segments.

Currently trading at $46.95, Prestige Consumer Healthcare has experienced a slight
dip, with a recent price change of -0.39 (-0.01%). Despite this minor fluctuation,
investors are eyeing the stock’s notable potential upside of 44.41%, driven by an
average target price of $67.80, according to analysts.

The company’s forward P/E ratio stands at 9.24, suggesting that the stock may be
undervalued compared to its earnings potential. While other valuation metrics such
as PEG, Price/Book, Price/Sales, and EV/EBITDA are not available, the forward P/
E provides a glimpse into its future growth prospects. Revenue growth at 6.50% is
a positive indicator of the company’s expanding operations, while an EPS of 3.57
further underscores its profitability.

Prestige Consumer Healthcare has achieved a commendable return on equity of 9.12%,
reflecting effective management and a robust business model. Free cash flow of approximately
$147.89 million highlights the company’s capacity to reinvest in growth opportunities
or reduce debt, adding to its financial stability.

Although the company does not offer a dividend, the absence of payout reflects a
strategic choice to reinvest earnings back into the business, potentially enhancing
shareholder value over the long term.

Analyst sentiment towards Prestige Consumer Healthcare is overwhelmingly positive,
with five buy ratings and two hold ratings, and no sell ratings. This confidence
is bolstered by a target price range of $55.00 to $75.00, indicating strong expectations
for future price appreciation.

Technical indicators present a mixed picture. The 50-day moving average of $50.74
and a 200-day moving average of $56.58 suggest that the stock is below its recent
historical performance levels, potentially offering a buying opportunity at its 
current price. Meanwhile, the RSI (14) at 55.91 and a MACD of -0.64 against a signal
line of 0.00 suggest that the stock is neither overbought nor oversold, providing
a neutral short-term outlook.

Prestige Consumer Healthcare’s product portfolio is extensive, featuring well-known
brands such as BC, Goody’s, Boudreaux’s Butt Paste, Chloraseptic, Clear Eyes, Compound
W, and many others. The company’s ability to market and distribute a diverse range
of health and personal care products across multiple channels, including e-commerce,
positions it well to capitalize on the growing demand for OTC products.

Founded in 1996 and formerly known as Prestige Brands Holdings, Inc., the company
has evolved significantly, with its 2018 rebranding to Prestige Consumer Healthcare
Inc. marking a new chapter in its growth story. As investors consider their options,
Prestige Consumer Healthcare Inc. presents a compelling case with its strong analyst
support, potential upside, and strategic growth initiatives in the OTC healthcare
market.

Share on:
